DePuy Orthopaedics, a division of Johnson & Johnson, is warning that its ASR hip implant has a high failure rate in some patients. This warning comes after the company announced last year it would phase out sales of the implant due to slowing sales, according to a report by the New York Times.
Studies have suggested the implant had higher failure rates than traditional hip replacements and has failed in some patients only a few years after implant due to metallic debris caused by an improperly implanted hip, according to the report.
Some physicians are criticizing DePuy for not stopping sales of the device earlier as evidence of the failing implants has been available "for some time," according to the report.
Read the New York Times´ report on the DePuy ASR hip implant.
Studies have suggested the implant had higher failure rates than traditional hip replacements and has failed in some patients only a few years after implant due to metallic debris caused by an improperly implanted hip, according to the report.
Some physicians are criticizing DePuy for not stopping sales of the device earlier as evidence of the failing implants has been available "for some time," according to the report.
Read the New York Times´ report on the DePuy ASR hip implant.